RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
BioMarin Pharmaceutical Stock

BioMarin Pharmaceutical ROA 2025

BioMarin Pharmaceutical ROA

0.02

Ticker

BMRN

ISIN

US09061G1013

WKN

924801

In 2025, BioMarin Pharmaceutical's return on assets (ROA) was 0.02, a 10.32% increase from the 0.02 ROA in the previous year.

BioMarin Pharmaceutical Aktienanalyse

What does BioMarin Pharmaceutical do?

Biomarin Pharmaceutical Inc is a biopharmaceutical company that focuses on the development and commercialization of therapies for rare genetic diseases. The company was founded in 1997 and is headquartered in San Rafael, California. BioMarin Pharmaceutical ist eines der beliebtesten Unternehmen auf Eulerpool.com.

BioMarin Pharmaceutical revenue by segment

  • 100 % Development & Commercialization of Innovative Therapies

ROA Details

Understanding BioMarin Pharmaceutical's Return on Assets (ROA)

BioMarin Pharmaceutical's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing BioMarin Pharmaceutical's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider BioMarin Pharmaceutical's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in BioMarin Pharmaceutical’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about BioMarin Pharmaceutical stock

What is the Return on Assets (ROA) of BioMarin Pharmaceutical this year?

The Return on Assets (ROA) of BioMarin Pharmaceutical is 0.02 undefined this year.

What was the ROA of BioMarin Pharmaceutical compared to the previous year?

The ROA of BioMarin Pharmaceutical has increased by 10.32% compared to the previous year.

What consequences do high ROA have for investors of BioMarin Pharmaceutical?

A high ROA is advantageous for investors of BioMarin Pharmaceutical, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in BioMarin Pharmaceutical?

A low ROA can be unfavorable for investors of BioMarin Pharmaceutical as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of BioMarin Pharmaceutical affect the company?

An increase in ROA of BioMarin Pharmaceutical can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of BioMarin Pharmaceutical impact the company?

A reduction in the ROA of BioMarin Pharmaceutical can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of BioMarin Pharmaceutical?

Some factors that can influence the ROA of BioMarin Pharmaceutical include revenue, operating costs, asset structure, and industry average.

Why is the ROA of BioMarin Pharmaceutical important for investors?

The ROA of BioMarin Pharmaceutical is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can BioMarin Pharmaceutical take to improve ROA?

To improve ROA, BioMarin Pharmaceutical can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does BioMarin Pharmaceutical pay?

Over the past 12 months, BioMarin Pharmaceutical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BioMarin Pharmaceutical is expected to pay a dividend of 0 USD.

What is the dividend yield of BioMarin Pharmaceutical?

The current dividend yield of BioMarin Pharmaceutical is .

When does BioMarin Pharmaceutical pay dividends?

BioMarin Pharmaceutical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of BioMarin Pharmaceutical?

BioMarin Pharmaceutical paid dividends every year for the past 0 years.

What is the dividend of BioMarin Pharmaceutical?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is BioMarin Pharmaceutical located?

BioMarin Pharmaceutical is assigned to the 'Health' sector.

Wann musste ich die Aktien von BioMarin Pharmaceutical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of BioMarin Pharmaceutical from 2/10/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 2/10/2025.

When did BioMarin Pharmaceutical pay the last dividend?

The last dividend was paid out on 2/10/2025.

What was the dividend of BioMarin Pharmaceutical in the year 2024?

In the year 2024, BioMarin Pharmaceutical distributed 0 USD as dividends.

In which currency does BioMarin Pharmaceutical pay out the dividend?

The dividends of BioMarin Pharmaceutical are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The BioMarin Pharmaceutical stock can be added to a savings plan with the following providers: Consorsbank

Andere Kennzahlen von BioMarin Pharmaceutical

Our stock analysis for BioMarin Pharmaceutical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioMarin Pharmaceutical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.